Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05298592 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT05298592 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 77 participants.
The verdict
NCT05298592, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with advanced tumors.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- BIOLOGICAL Nivolumab
- BIOLOGICAL BMS-986406
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2024-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05298592
The ClinicalTrials.gov registry entry for NCT05298592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT05298592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05298592 about?
NCT05298592 is a clinical study titled "A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors". The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with advanced tumors.
What is the current status of trial NCT05298592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2022-03-31. Estimated completion is 2024-08-16.
What interventions are being tested in trial NCT05298592?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nivolumab (BIOLOGICAL), BMS-986406 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05298592?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.